US3911915A - Dialytic introduction of maltose into bloodstream - Google Patents
Dialytic introduction of maltose into bloodstream Download PDFInfo
- Publication number
- US3911915A US3911915A US286409A US28640972A US3911915A US 3911915 A US3911915 A US 3911915A US 286409 A US286409 A US 286409A US 28640972 A US28640972 A US 28640972A US 3911915 A US3911915 A US 3911915A
- Authority
- US
- United States
- Prior art keywords
- maltose
- solution
- glucose
- animals
- animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1654—Dialysates therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
- A61M1/287—Dialysates therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S128/00—Surgery
- Y10S128/03—Heart-lung
Definitions
- the invention is concerned with an improved method of feeding warm blooded animals, more specifically with a substitute for a standard glucose presently used for that purpose.
- glucose solutions have been used to provide calories for patients who are unable, for one reason or another, to eat normally, they present certain problems and limitations. Diabetics or pre-diabetics do not tolerate glucose well and, in addition, even many normal paticnts may react unfavorably to the administration of this sugar. Some go into a reactive hypoglycemia.
- glucose has been administered intravenously either into a peripheral vein or into a large vein.
- a maximum concentration of 5% can be used and about 4 liters per day are infused.
- the increased osmotic pressure may irritate the vessel walls and will induce problems of fluid balance in the patient.
- the use of such solutions will cause first a deep hyperglycemia which, in turn, causes a hyper secretion of insulin which, ultimately, results in hypoglycemia. If a greater than 4 liter volume per day is attempted this may cause difficulties in patients with cardiac or renal disease.
- Glucose is sometimes administered as a hypertonic solution l0 20%) into a large vein such as the superior vena cava. In such case 3 liters of a 20% solution may be used daily. However, these solutions frequently provoke metabolic responses which are not always easy to control.
- the present invention is intended to accomplish the foregoing objectives and consists in the substitution of maltose for the previously used glucose. It will be appreciated that one of the limiting factor in the use of glucose is the osmotic pressure generated by the solution. If the osmotic pressure exceeds that of the body cells, water from the interior of the cells will tend to pass through the cell walls by reverse osmosis. Thus, a serious problem can arise when the feeding is to take place over a long period of time.
- a maltose solution has an osmotic pressure which is approximately one-half that of a correspondingly concentrated solution of glucose. This permits the administration of a solution of maltose and enables the introduction into the body of at least twice the number of calories which can be given using the glucose solution.
- the maltose solution can be introduced intravenousl y, intraperitoneally or subcutaneously. It can constitute all or part of the total diet of the patient. Additional nutrients can be included in the solution including amino acids, vitamins, minerals and the like. Moreover, medication may also be dissolved in the solution and administered to the patient along with the maltose.
- maltose should be suitable for this purpose since two very common disaccharides (sucrose and lactose) are ineffective when given parenterally. This is true even though both of these sugars are, of course, fully utilizable and metabolizable when taken orally. It would be expected that maltose which is also a disaccharide similar to sucrose and lactose would also be ineffective when given parenterally.
- EXAMPLE 1 Male SpragueDawley rats weighing 275 gm each were the subjects of this experiement. These animals at the age tested had a slow growth rate. The rats were divided into four groups and all were housed individually in metabolic cages so that no portion of the diet was lost. These cages permit the collection of any food which the animals may spill so that it can be re-fed to the rats.
- the animals were fed a diet of Rockland Chow and were also given maltose parenterally.
- the animals in Groups B, C and D each received 10 gm of Rockland Chow per day. This amount is less than 50% of that consumed by the animals in Group A. It contains an adequate amount of protein (2.1 gm per rat per day). It does not contain enough digestible carbohydrates to maintain body weight.
- the oral intake of the various groups is set forth in Table I.
- the animals were weighed twice daily and were killed after five days of the experiment. No abnormalities were noted and, in particular, the liver weights were all within normal range indicating generally healthy animals,
- Group A was given as its total diet a 10% maltose solution containing 2 cc per 100 ml of McGaw Hyprotigen.
- Hyprotigen is a protein hydrolysate containing mixed amino acids and minerals. It is normally used as a supplement to glucose solutions.
- the animals were given, intravenously, cc of this solution per kg of body weight per day spread out over a period of 12 hours.
- Group B was treated the same as Group A except that the solution administered contained 5% glucose instead of 10% maltose.
- the novel method is useful as a replacement for glucose in the intravenous feeding of animals, including humans. It can constitute all or part of the total diet.
- the method is useful in cases of peritoneal dialysis wherein fluid is introduced into the peritoneal cavity in order to absorb poisons or the like from the system. The fluid is then withdrawn and replaced by fresh fluid until the treatment is complete. This treatment is also used to take the place of an artificial kidney machine when there is either lack of availability of such machine or the patient has only a mild kidney illness.
- this method can be used in connection with full scale blood dialysis.
- Introduction of maltose into the dialyzing fluid enables the treatment to introduce calories into the bloodstream while, at thesame time, not increasing the osmotic pressure beyond normal levels.
- a method of nourishing a warm blooded animal comprising providing a solution of maltose in a pharmaceutically acceptable carrier, introducing said solution into said animals intraperitoneally, and then withdrawing said solution from said animal.
- a method of nourishing a warm blooded animal comprising providing a solution of maltose in a pharmaceutically acceptable carrier, introducing said solution into a dialysing fluid, impinging blood from said animal on one side of a dialysis membrane, said dialysing fluid containing said solution being on the other side of said membrane, permitting said maltose to pass through said membrane into said blood, and then re-
Abstract
A method of nourishing warm blooded animals comprising the parenteral introduction of a maltose solution in a pharmaceutically acceptable carrier into the living body. The solution may constitute all or part of the total diet and may be supplemented by amino acids, vitamins, minerals and/or medication. The method may also be used as part of blood dialysis as, for example, in the case of kidney failure.
Description
United States Patent Seifter et a1.
DIALYTIC INTRODUCTION OF MALTOSE INTO BLOODSTREAM Inventors: Eli Seifter, New Hyde Park;
Giuseppe Rettura, Bronx, both of N.Y.
Albert Einstein College of Medicine, New York, NY.
Filed: Sept. 5, 1972 App]. No.: 286,409
[73] Assignee:
US. Cl 128/214 R; 128/213; 128/D1G. 3; 210/22; 424/180 Int. Cl. A61M 5/00; A61M l/O3 Field of Search 424/180; 128/214 R, 214.2, 128/213, DIG. 3; 23/2585; 210/22, 321
References Cited UNITED STATES PATENTS 5/1967 Dyke 424/180 GLUCOSE MALTOSE AVERAGE WEIGHT LOSS, lN HUNDRED GRAMS/DOG 1 Oct. 14, 1975 9/ 1969 Revici 424/ 1 80 8/1970 Roberts 210/22 Primary ExaminerDalton L. Truluck Attorney, Agent, or Firm-Bierman & Bierman 2 Claims, 1 Drawing Figure DAYS ON DIET US. Patent Oct. 14, 1975 3,911,915
GLUCOSE MALTOSE AVERAGE WEIGHT LOSS, 1N HUNDRED GRAMS/DOG Ullllllllllllllllllllllllllllllllllllllllllllllllllllll DAYS ON DIET DIALYTIC INTRODUCTION OF MALTOSE INTO BLOODSTREAM The invention described herein was made in the course of work under a grant or award from the Department of Health, Education, and Welfare.
The invention is concerned with an improved method of feeding warm blooded animals, more specifically with a substitute for a standard glucose presently used for that purpose.
While glucose solutions have been used to provide calories for patients who are unable, for one reason or another, to eat normally, they present certain problems and limitations. Diabetics or pre-diabetics do not tolerate glucose well and, in addition, even many normal paticnts may react unfavorably to the administration of this sugar. Some go into a reactive hypoglycemia.
Furthermore, by the use of the existing glucose administration it is not possible to provide much more than about 800 calories per day. This is far lower than is required to sustain the normal human being at an appropriate weight. Moreover, large volumes of water are required since the maximum concentration suitable is a 5% solution of glucose.
In the pre-existing practice glucose has been administered intravenously either into a peripheral vein or into a large vein. In the former case a maximum concentration of 5% can be used and about 4 liters per day are infused. If a stronger solution is used, the increased osmotic pressure may irritate the vessel walls and will induce problems of fluid balance in the patient. The use of such solutions will cause first a deep hyperglycemia which, in turn, causes a hyper secretion of insulin which, ultimately, results in hypoglycemia. If a greater than 4 liter volume per day is attempted this may cause difficulties in patients with cardiac or renal disease.
Glucose is sometimes administered as a hypertonic solution l0 20%) into a large vein such as the superior vena cava. In such case 3 liters of a 20% solution may be used daily. However, these solutions frequently provoke metabolic responses which are not always easy to control.
There is a definite need for a treatment that will provide from 1600 to 2400 calories per day and, at the same time, avoid the necessity of entering a large blood vessel. In addition, such improved treatment should minimize swings in blood glucose and should be capable of being given intermittently.
The present invention is intended to accomplish the foregoing objectives and consists in the substitution of maltose for the previously used glucose. It will be appreciated that one of the limiting factor in the use of glucose is the osmotic pressure generated by the solution. If the osmotic pressure exceeds that of the body cells, water from the interior of the cells will tend to pass through the cell walls by reverse osmosis. Thus, a serious problem can arise when the feeding is to take place over a long period of time.
It has been found that a maltose solution has an osmotic pressure which is approximately one-half that of a correspondingly concentrated solution of glucose. This permits the administration of a solution of maltose and enables the introduction into the body of at least twice the number of calories which can be given using the glucose solution.
The maltose solution can be introduced intravenousl y, intraperitoneally or subcutaneously. It can constitute all or part of the total diet of the patient. Additional nutrients can be included in the solution including amino acids, vitamins, minerals and the like. Moreover, medication may also be dissolved in the solution and administered to the patient along with the maltose.
It is quite surprising that maltose should be suitable for this purpose since two very common disaccharides (sucrose and lactose) are ineffective when given parenterally. This is true even though both of these sugars are, of course, fully utilizable and metabolizable when taken orally. It would be expected that maltose which is also a disaccharide similar to sucrose and lactose would also be ineffective when given parenterally.
In order to demonstrate the usefulness of maltose for the purposes described the following examples are included. They are intended to be illustrative only and do not constitute any limitation on the invention.
EXAMPLE 1 Male SpragueDawley rats weighing 275 gm each were the subjects of this experiement. These animals at the age tested had a slow growth rate. The rats were divided into four groups and all were housed individually in metabolic cages so that no portion of the diet was lost. These cages permit the collection of any food which the animals may spill so that it can be re-fed to the rats.
The animals were fed a diet of Rockland Chow and were also given maltose parenterally.
The animals in Group A received as much Chow as they desired. Food was always present in their cups and they were permitted to eat ad libitum.
The animals in Groups B, C and D each received 10 gm of Rockland Chow per day. This amount is less than 50% of that consumed by the animals in Group A. It contains an adequate amount of protein (2.1 gm per rat per day). It does not contain enough digestible carbohydrates to maintain body weight. The oral intake of the various groups is set forth in Table I.
TABLE 1 Protein Intake Calorie Intake Group (gm per rat per day) (per rat per day) A 5.3 B 2.1 40 C 2.1 40 D 2.1 40
be appreciated that for human beings the comparable concentrations would be 5% and 10%, respectively. These'solutions are, of course, not isocaloric.
The animals were weighed twice daily and were killed after five days of the experiment. No abnormalities were noted and, in particular, the liver weights were all within normal range indicating generally healthy animals,
The results of the treatment are set forth in Table ll.
TABLE I1 Weight Gain (gm) Group per rat in days A 10.6 B I4.U C 9.8 D 4.3
It can thus be seen that the animals on maltose gained almost 1 gm per day while the animals on glucose lost approximately 2 gm per day.
Alternatively, the results can be expressed in accordance with the following Table:
Male Sprague-Dawley rats weighing 330 gm each were divided into three groups of six rats. They were each fed gm daily of Rockland Chow. This was a greater restriction of food intake than in Example 1 since the animals were heavier. in addition to the oral feeding each animal received by intraperitoneal injection the following: 5 times daily Group A 3 ml of 0.45% sodium chloride Group B 3 ml of 5% glucose Group C 3 ml of 5% maltose After 4 days, the following weight changes were noted:
TABLE IV Weight loss (gm) Group per rat A 27 B 17 C 16 In this experiment the rats were given iso-caloric amounts of glucose and maltose. They reacted similarly in both cases. Groups B and C lost substantially less weight than the animals receiving only salt injections. This demonstrates that the maltose calories are equally available to the body as glucose calories.
EXAMPLE 3 Dogs initially weighing between 20 and 40 kg were divided into two groups. Group A was given as its total diet a 10% maltose solution containing 2 cc per 100 ml of McGaw Hyprotigen. Hyprotigen is a protein hydrolysate containing mixed amino acids and minerals. It is normally used as a supplement to glucose solutions. The animals were given, intravenously, cc of this solution per kg of body weight per day spread out over a period of 12 hours. Group B was treated the same as Group A except that the solution administered contained 5% glucose instead of 10% maltose.
The regimen was continued for three days after which Group A was switched to glucose and Group B was given the maltose. At the end of six days the reversal took place again.
The results of this test are set forth in the single FIG- URE annexed hereto and made a part hereof.
From the foregoing it can be seen that the novel method is useful as a replacement for glucose in the intravenous feeding of animals, including humans. It can constitute all or part of the total diet.
It is also especially useful when subcutaneous infusion is used in the treatment of infants suffering from dehydration and malnutrition. This occurs when an infant is suffering from an illness which causes vomiting or diarrhea.
The method is useful in cases of peritoneal dialysis wherein fluid is introduced into the peritoneal cavity in order to absorb poisons or the like from the system. The fluid is then withdrawn and replaced by fresh fluid until the treatment is complete. This treatment is also used to take the place of an artificial kidney machine when there is either lack of availability of such machine or the patient has only a mild kidney illness.
In addition, this method can be used in connection with full scale blood dialysis. Introduction of maltose into the dialyzing fluid enables the treatment to introduce calories into the bloodstream while, at thesame time, not increasing the osmotic pressure beyond normal levels. There is a tendency during dialysis toward loss of sugar from the blood. Previously 2 gm of glucose per liter of fluid was added in order to prevent this. If, as suggested herein, 1 gm of glucose is substituted by 2 gm of maltose (thus keeping the total osmotic pressure the same) the additional calories can be given.
As can be seen from the foregoing description the invention is to be broadly construed and not to be limited except by the character of the claims appended hereto.
What we claim is:
1. A method of nourishing a warm blooded animal comprising providing a solution of maltose in a pharmaceutically acceptable carrier, introducing said solution into said animals intraperitoneally, and then withdrawing said solution from said animal.
2. A method of nourishing a warm blooded animal comprising providing a solution of maltose in a pharmaceutically acceptable carrier, introducing said solution into a dialysing fluid, impinging blood from said animal on one side of a dialysis membrane, said dialysing fluid containing said solution being on the other side of said membrane, permitting said maltose to pass through said membrane into said blood, and then re-
Claims (2)
1. A method of nourishing a warm blooded animal comprising providing a solution of maltose in a pharmaceutically acceptable carrier, introducing said solution into said animals intraperitoneally, and then withdrawing said solution from said animal.
2. A method of nourishing a warm blooded animal comprising providing a solution of maltose in a pharmaceutically acceptable carrier, introducing said solution into a dialysing fluid, impinging blood from said animal on one side of a dialysis membrane, said dialysing fluid containing said solution being on the other side of said membrane, permitting said maltose to pass through said membrane into said blood, and then returning said blood into said animal.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US286409A US3911915A (en) | 1972-09-05 | 1972-09-05 | Dialytic introduction of maltose into bloodstream |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US286409A US3911915A (en) | 1972-09-05 | 1972-09-05 | Dialytic introduction of maltose into bloodstream |
Publications (1)
Publication Number | Publication Date |
---|---|
US3911915A true US3911915A (en) | 1975-10-14 |
Family
ID=23098472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US286409A Expired - Lifetime US3911915A (en) | 1972-09-05 | 1972-09-05 | Dialytic introduction of maltose into bloodstream |
Country Status (1)
Country | Link |
---|---|
US (1) | US3911915A (en) |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4021544A (en) * | 1976-07-12 | 1977-05-03 | American Cyanamid Company | Complement inhibitors |
US4095000A (en) * | 1974-05-17 | 1978-06-13 | Max Brenner | Protein-saving foodstuff and fodder additive |
US4154822A (en) * | 1976-08-02 | 1979-05-15 | The University Of Chicago | Polysaccharide for enhancement of cardiac output |
US4322275A (en) * | 1980-01-10 | 1982-03-30 | Ionics Incorporated | Fractionation of protein mixtures |
US4351710A (en) * | 1980-01-10 | 1982-09-28 | Ionics, Incorporated | Fractionation of protein mixtures |
WO1983000087A1 (en) * | 1981-07-10 | 1983-01-20 | Baxter Travenol Lab | Peritoneal dialysis solution containing carbohydrate polymers |
US4761237A (en) * | 1981-07-10 | 1988-08-02 | Baxter Travenol Laboratories, Inc. | Peritoneal dialysis solution containing carbohydrate polymers |
US4879280A (en) * | 1981-09-24 | 1989-11-07 | Fresenius Ag | Dialysis solution for use in intraperitoneal dialysis |
US4976683A (en) * | 1986-06-20 | 1990-12-11 | Abbott Laboratories | Peritoneal dialysis method |
US5011826A (en) * | 1988-04-15 | 1991-04-30 | Fresenius Ag | Aqueous dialysis and rinsing solution for intraperitoneal administration |
WO1991014435A1 (en) * | 1990-03-19 | 1991-10-03 | Brigham And Women's Hospital | Treatment of osmotic disturbance with organic osmolytes |
US5114932A (en) * | 1990-11-30 | 1992-05-19 | Runge Thomas M | Hyperosmolar oxyreplete hemosubstitute |
US5122516A (en) * | 1989-05-26 | 1992-06-16 | Terumo Kabushiki Kaisha | Preparation for blood dialysis and method for production thereof |
US5182299A (en) * | 1990-03-19 | 1993-01-26 | Brigham And Women's Hospital | Treatment of osmotic disturbance with organic osmolytes |
WO1998029434A1 (en) * | 1996-12-31 | 1998-07-09 | Ford Henry Health System | Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients |
WO1999001144A1 (en) | 1997-07-04 | 1999-01-14 | Allied Therapeutics Limited | Peritoneal dialysis fluid |
US6689275B1 (en) * | 1996-12-31 | 2004-02-10 | Ajay Gupta | Method and pharmaceutical composition for replacing iron losses in dialysis patients |
US6779468B1 (en) | 1997-08-07 | 2004-08-24 | Ajay Gupta | Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients |
US6841172B1 (en) | 1996-08-14 | 2005-01-11 | Hemocleanse, Inc. | Method for iron delivery to a patient by transfer from dialysate |
US7208092B2 (en) | 2002-07-19 | 2007-04-24 | Baxter International Inc. | Systems and methods for peritoneal dialysis |
US20100051552A1 (en) * | 2008-08-28 | 2010-03-04 | Baxter International Inc. | In-line sensors for dialysis applications |
US7867214B2 (en) | 2002-07-19 | 2011-01-11 | Baxter International Inc. | Systems and methods for performing peritoneal dialysis |
US7922686B2 (en) | 2002-07-19 | 2011-04-12 | Baxter International Inc. | Systems and methods for performing peritoneal dialysis |
US10232103B1 (en) | 2001-11-13 | 2019-03-19 | Baxter International Inc. | System, method, and composition for removing uremic toxins in dialysis processes |
US10646634B2 (en) | 2008-07-09 | 2020-05-12 | Baxter International Inc. | Dialysis system and disposable set |
US11495334B2 (en) | 2015-06-25 | 2022-11-08 | Gambro Lundia Ab | Medical device system and method having a distributed database |
US11516183B2 (en) | 2016-12-21 | 2022-11-29 | Gambro Lundia Ab | Medical device system including information technology infrastructure having secure cluster domain supporting external domain |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3322629A (en) * | 1963-06-14 | 1967-05-30 | Evans Medical Ltd | Injectable aqueous solutions containing a protamine-active compound |
US3470295A (en) * | 1965-01-12 | 1969-09-30 | Emanuel Revici | Compositions and methods for treating posttraumatic shock,pain and hemorrhage |
US3525686A (en) * | 1968-03-19 | 1970-08-25 | American Hospital Supply Corp | Hemodialysis solution containing sorbitol and method of using same |
-
1972
- 1972-09-05 US US286409A patent/US3911915A/en not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3322629A (en) * | 1963-06-14 | 1967-05-30 | Evans Medical Ltd | Injectable aqueous solutions containing a protamine-active compound |
US3470295A (en) * | 1965-01-12 | 1969-09-30 | Emanuel Revici | Compositions and methods for treating posttraumatic shock,pain and hemorrhage |
US3525686A (en) * | 1968-03-19 | 1970-08-25 | American Hospital Supply Corp | Hemodialysis solution containing sorbitol and method of using same |
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4095000A (en) * | 1974-05-17 | 1978-06-13 | Max Brenner | Protein-saving foodstuff and fodder additive |
US4021544A (en) * | 1976-07-12 | 1977-05-03 | American Cyanamid Company | Complement inhibitors |
US4154822A (en) * | 1976-08-02 | 1979-05-15 | The University Of Chicago | Polysaccharide for enhancement of cardiac output |
US4322275A (en) * | 1980-01-10 | 1982-03-30 | Ionics Incorporated | Fractionation of protein mixtures |
US4351710A (en) * | 1980-01-10 | 1982-09-28 | Ionics, Incorporated | Fractionation of protein mixtures |
WO1983000087A1 (en) * | 1981-07-10 | 1983-01-20 | Baxter Travenol Lab | Peritoneal dialysis solution containing carbohydrate polymers |
JPS58501077A (en) * | 1981-07-10 | 1983-07-07 | バクスター・インターナショナル・インコーポレイテッド | Peritoneal dialysis fluid containing carbohydrate polymer |
US4761237A (en) * | 1981-07-10 | 1988-08-02 | Baxter Travenol Laboratories, Inc. | Peritoneal dialysis solution containing carbohydrate polymers |
US4879280A (en) * | 1981-09-24 | 1989-11-07 | Fresenius Ag | Dialysis solution for use in intraperitoneal dialysis |
US4976683A (en) * | 1986-06-20 | 1990-12-11 | Abbott Laboratories | Peritoneal dialysis method |
US5011826A (en) * | 1988-04-15 | 1991-04-30 | Fresenius Ag | Aqueous dialysis and rinsing solution for intraperitoneal administration |
US5122516A (en) * | 1989-05-26 | 1992-06-16 | Terumo Kabushiki Kaisha | Preparation for blood dialysis and method for production thereof |
WO1991014435A1 (en) * | 1990-03-19 | 1991-10-03 | Brigham And Women's Hospital | Treatment of osmotic disturbance with organic osmolytes |
US5182299A (en) * | 1990-03-19 | 1993-01-26 | Brigham And Women's Hospital | Treatment of osmotic disturbance with organic osmolytes |
US5114932A (en) * | 1990-11-30 | 1992-05-19 | Runge Thomas M | Hyperosmolar oxyreplete hemosubstitute |
US20050148663A1 (en) * | 1996-08-14 | 2005-07-07 | Ash Stephen R. | Method for iron delivery to a patient by transfer from dialysate |
US6841172B1 (en) | 1996-08-14 | 2005-01-11 | Hemocleanse, Inc. | Method for iron delivery to a patient by transfer from dialysate |
US20040175431A1 (en) * | 1996-12-31 | 2004-09-09 | Ajay Gupta | Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients |
AU736053B2 (en) * | 1996-12-31 | 2001-07-26 | Ajay Gupta | Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients |
WO1998029434A1 (en) * | 1996-12-31 | 1998-07-09 | Ford Henry Health System | Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients |
US6689275B1 (en) * | 1996-12-31 | 2004-02-10 | Ajay Gupta | Method and pharmaceutical composition for replacing iron losses in dialysis patients |
WO1999001144A1 (en) | 1997-07-04 | 1999-01-14 | Allied Therapeutics Limited | Peritoneal dialysis fluid |
US6779468B1 (en) | 1997-08-07 | 2004-08-24 | Ajay Gupta | Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients |
US10232103B1 (en) | 2001-11-13 | 2019-03-19 | Baxter International Inc. | System, method, and composition for removing uremic toxins in dialysis processes |
US10980931B2 (en) | 2001-11-13 | 2021-04-20 | Baxter International Inc. | System, method, and composition for removing uremic toxins in dialysis processes |
US10363352B2 (en) | 2002-07-19 | 2019-07-30 | Baxter International Inc. | Disposable set and system for dialysis |
US10179200B2 (en) | 2002-07-19 | 2019-01-15 | Baxter International Inc. | Disposable cassette and system for dialysis |
US7922686B2 (en) | 2002-07-19 | 2011-04-12 | Baxter International Inc. | Systems and methods for performing peritoneal dialysis |
US8357113B2 (en) | 2002-07-19 | 2013-01-22 | Baxter International Inc. | Systems and methods for performing peritoneal dialysis |
US8597227B2 (en) | 2002-07-19 | 2013-12-03 | Baxter International Inc. | Weight/sensor-controlled sorbent system for hemodialysis |
US8815095B2 (en) | 2002-07-19 | 2014-08-26 | Baxter International Inc. | Peritoneal dialysis systems and methods that regenerate dialysate |
US8998839B2 (en) | 2002-07-19 | 2015-04-07 | Baxter International Inc. | Systems and methods for performing peritoneal dialysis |
US9764074B1 (en) | 2002-07-19 | 2017-09-19 | Baxter International Inc. | Systems and methods for performing dialysis |
US9814820B2 (en) | 2002-07-19 | 2017-11-14 | Baxter International Inc. | Weight-controlled sorbent system for hemodialysis |
US7922911B2 (en) | 2002-07-19 | 2011-04-12 | Baxter International Inc. | Systems and methods for peritoneal dialysis |
US7867214B2 (en) | 2002-07-19 | 2011-01-11 | Baxter International Inc. | Systems and methods for performing peritoneal dialysis |
US11235094B2 (en) | 2002-07-19 | 2022-02-01 | Baxter International Inc. | System for peritoneal dialysis |
US7208092B2 (en) | 2002-07-19 | 2007-04-24 | Baxter International Inc. | Systems and methods for peritoneal dialysis |
US10646634B2 (en) | 2008-07-09 | 2020-05-12 | Baxter International Inc. | Dialysis system and disposable set |
US20100051552A1 (en) * | 2008-08-28 | 2010-03-04 | Baxter International Inc. | In-line sensors for dialysis applications |
US11400193B2 (en) | 2008-08-28 | 2022-08-02 | Baxter International Inc. | In-line sensors for dialysis applications |
US11495334B2 (en) | 2015-06-25 | 2022-11-08 | Gambro Lundia Ab | Medical device system and method having a distributed database |
US11516183B2 (en) | 2016-12-21 | 2022-11-29 | Gambro Lundia Ab | Medical device system including information technology infrastructure having secure cluster domain supporting external domain |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3911915A (en) | Dialytic introduction of maltose into bloodstream | |
Doolan et al. | An evaluation of intermittent peritoneal lavage | |
Filler et al. | Care of the critically ill child: Intravenous alimentation | |
MXPA06014254A (en) | Bicarbonate-based peritoneal dialysis solutions. | |
CA1187801A (en) | Dialysis solution containing glycerol | |
EP0077354A1 (en) | Dialysis solution containing glucose, amino acids & insulin | |
EP0076355A2 (en) | Improved peritoneal dialysis solution | |
Myschetzky et al. | Urea-induced, osmotic diuresis and alkalization of urine in acute barbiturate intoxication | |
Aperia et al. | Renal control of sodium and fluid balance in newborn infants during intravenous maintenance therapy | |
Davenport et al. | Management of patients with renal failure complicated by cerebral oedema | |
Dudrick et al. | Total intravenous feeding | |
Madden et al. | Continuous ambulatory peritoneal dialysis in diabetes mellitus: The risks and benefits of intraperitoneal insulin | |
Yeo et al. | Total intravenous nutrition: Experience with fat emulsions and hypertonic glucose | |
Twardowski et al. | Three exchanges with a 2.5-liter volume for continuous ambulatory peritoneal dialysis | |
BELLOMO et al. | Acute continuous hemofiltration with dialysis: effect on insulin concentrations and glycemic control in critically ill patients | |
Reimold et al. | Use of hemodialysis in the treatment of quinidine poisoning | |
LOGSDON et al. | Death, probably due to potassium deficiency, following control of diabetic coma | |
Muth | Frusemide in severe renal insufficiency | |
Dudrick et al. | Long-term parenteral nutrition: its current status | |
KAISER et al. | Intravenous infusion of ascitic fluid | |
Johnson et al. | Experimental Studies on Fluid Pathophysiology in Small Intestinal Obstruction in the Rat: VI. Effects of Intraluminal Hyperosmolality and Simultaneous Intravenous Infusions on the Experimentally Obstructed Small Intestine of the Rat | |
Van Eys et al. | Safety of intravenous hyperalimentation in children with malignancies: A cooperative group trial | |
CA1219212A (en) | Opsonins in peritoneal dialysis | |
HOLLIDAY | Dialysis in pediatrics, including use of the artificial kidney | |
Gahl et al. | Clinical and metabolic aspects of continuous ambulatory peritoneal dialysis (CAPD) |